Interview with Craig Moore, Director, Hahn Healthcare
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Address: Level 7, 50 Berry Street
North Sydney NSW 2060
Tel: 02 9959 5533
Web: http://www.hahnhealthcare.com.au/default.aspx
Hahn Healthcare combines innovative solutions and world-class services with market insight to create value in your business.
Hahn Healthcare offers clients access to: the highest quality people, industry leading solutions, innovative services, and new market opportunities.
Founded in 1994, Hahn Healthcare is a trusted partner with a reputation for excellence.
Innovative solutions. Market insight. Trusted Partnerships.
As a market leader, Hahn Healthcare is a trusted partner of key decision makers in the Australian pharmaceutical and medical device industries.
We are uniquely positioned to identify partner organisations and market opportunities for global healthcare products, including pharmaceutical and medical devices.
Our team partners with international companies to deliver global solutions locally. We provide strategic advice based on deep industry knowledge and create an access point to the Australian market.
Hahn Healthcare helps international companies reduce risk, manage regulatory requirements and create new revenue streams by facilitating the delivery of global solutions to the Australian marketplace.
Hahn Healthcare is committed to excellence. We build partnerships based on integrity, mutual respect and trust. We are transparent, accountable and operate according to the highest professional standards.
Can you outline the significance of the current PBS to the industry and in particular the impact it has on service providers to the industry such as Hahn? As service…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
See our Cookie Privacy Policy Here
